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The most compelling evidence that lymphocytes meditate an anti-leukemia effect comes from studies where allogeneic donor lymphocyte infusions (DLI) have been used to treat relapse of myeloid leukemia after allogeneic BMT (Antin, 1993; Giralt and Kolb, 1996; Kolb and Holler, 1997; Kolb et al., 1995 Kolb et al., , 1996 . Lymphocyte transfusion from the original bone marrow (BM) donor induces both hematological and cytogenetic responses in approximately 70 -80% of patients with myelogenous leukemia in chronic phase . A complete cytogenetic response is usually obtained between 1 -4 months after DLI (van Rhee et al., 1994) and approximately 80% of responders will achieve reverse transcriptase-polymerase chain reaction (RT -PCR) negativity for the bcrabl translocation (the fusion product of the t(9;22) translocation found in chronic myelogenous leukemia (CML)) within a mean of 6 months (van Rhee et al., 1994) . Acute myelogenous leukemia (AML) is also susceptible to the graft-versus-leukemia (GVL) effect, with 15 -40% of patients obtaining remission with DLI alone (Collins et al., 1997) . While significant graftversus-host disease (GVHD) occurs in 50% of patients treated with DLI, and disease response occurs in 90% of CML patients, 55% of patients who do not get GVHD also have disease response (Giralt and Kolb, 1996; Kolb and Holler, 1997) . This demonstrates that GVL is separable from GVHD in some patients, although only a handful of antigens that drive the donor's lymphocyte response preferentially against the leukemia have been identified. Remissions after DLI for AML are generally not as durable as those obtained in CML, which may reflect the rapid kinetics of tumor growth outpacing the kinetics of the developing immune response. However, if more antigens could be determined, and if large numbers of antigen-specific cytotoxic T-lymphocytes (CTLs) could be obtained, it would allow for development of leukemia-specific therapies using the antigens as a targets for generating specific T-cells for use in adoptive immunotherapy.
To understand the nature of GVL and GVHD, we must review some of the principles of antigen recognition and highlight a recent discovery that has aided our ability to study T-cell interactions. T-cells recognize peptide antigens that are presented on the cell surface in combination with major histocompatibility complex (MHC) antigens. Peptides derived from cytoplasmic proteins that are 8 to 11 amino acids in length, bind in the groove of class I MHC molecules and are transported via the endoplasmic reticulum to the cell surface. Larger peptides, typically 12 -18 amino acids in length, that are derived from cell processing of extracellular proteins, bind class II MHC molecules and are presented to T-cells on the cell surface. Both peptide/MHC-I and peptide/MHC-II are recognized by the heterodimeric T-cell receptor (TCR) on CD8 or CD4 T-lymphocytes, respectively, with rapid off rates and k D in the range of 10 74 to 10 75 M (Alam et al., 1996) . Points of contact between the TCR and the peptide/MHC surface include surface amino acids contributed by the two alpha helical domains of the MHC molecule that flank the peptide antigen binding pocket, as well as amino acids from the peptide itself.
Our understanding of the nature of antigen-specific T-cell responses has been greatly improved by the discovery that antigen-specific TCR can be reversibly labeled with soluble peptide/MHC tetramers (Altman et al., 1996) . Peptide antigen, b 2 -microglobulin and the MHC-I heavy-chain are folded together, and, via a biotinylation signal sequence at the C-terminus of the MHC-I heavy-chain, are linked covalently to streptavidin in a 4 : 1 molecular ratio. When the streptavidin molecule is linked to a fluorescent dye such as phycoerythrin, the resulting peptide/MHC tetramers can be used to identify antigen-specific T-cells by FACS analysis because of their higher binding avidity to the TCR. Using tetramers, it has been determined that up to 45% of all peripheral circulating T-cells may be specific for a single dominant antigen at the height of an immune response to EBV infection (Callan et al., 1998) and similar dominance may be seen during other viral infections (Komanduri et al., 1998 (Komanduri et al., , 2001 ).
Tetramers have also been used to study immune responses to tumor antigens , and they have also aided in their discovery .
Various methods have been used to determine the nature of the target antigens of the GVL effect. For instance, tissue-restricted minor histocompatibility antigens (mHA) that are derived from proteins expressed only in hematopoietic tissue have been shown to be the targets of alloreactive T-cells. These mHA result from polymorphic differences between donor and recipient in the coding regions of peptide antigens that bind within the groove of MHC molecules and are recognized by donor T-cells. Heterologous T-cell clones that demonstrate alloreactivity toward mHA have been established from patients with severe GVHD following BMT with an HLAmatched donor (Faber et al., 1995a (Faber et al., ,b, 1996 van der Harst et al., 1994) . Some of these mHA-specific CTL clones react only with hematopoietic-derived cells, suggesting tissue specificity (Faber et al., 1996) , and therefore potentially shared antigens on leukemia. In one study, GVHD correlated closely with differences in the minor antigen HA-1 in HLA identical sibling transplants (Goulmy et al., 1996) . Expression of two human mHAs, identified as HA-1 and HA-2, is confined to hematopoietic tissues, and HA-2 was identified as a peptide derived from the non-filamentforming class I myosin family by using mHA-reactive CTL clones to screen peptide fractions eluted from MHC class I molecules (den Haan et al., 1995) . While this methodology has successfully defined some CTL alloantigens, it is extremely labor intensive and it is unclear whether CTL specific for any minor antigens identified thus far convey leukemia-specific immunity without concomitant GVHD. Adoptive cellular immunotherapy of leukemia using antigen-specific T-cells that target mHA may promote GVL and reduce GVHD if appropriate hematopoietic-restricted mHA could be targeted. However, a practical limit of any immunotherapy approach targeting these mHAs is that only 10% of individuals would be expected to have the relevant HA-1 alternate allele, and 51% would have the HA-2 alternate allele, which makes donor availability quite limiting.
An alternative immunological method to determine leukemia-specific CTL epitopes has been applied to determine whether BCR -ABL fusion region peptides could be used to elicit CML-specific T-cell responses. Using this method, peptides are synthesized, based upon an 'educated guess' of which proteins are potential target antigens for a selective anti-leukemia CTL response. The proteins are then examined for short peptides that fit the binding motif of the most common HLA alleles. These peptides are then synthesized, HLA binding is confirmed, and peptide-specific CTL responses are elicited in vitro. Since BCR -ABL is present in nearly all Philadelphia chromosome-positive CML patients, it is thought to represent a potentially unique leukemia antigen. The ABL coding sequences upstream (5') of exon II on chromosome 9 are translocated to chromosome 22 and fused in-frame with the BCR gene downstream (3') of exon III, resulting in a chimeric mRNA (b3a2) (the most common transcript) which is translated into a chimeric protein (p210 BCR-ABL ). Translation of b3a2 mRNA results in the coding of a unique amino acid (lysine) within the fusion region. Some HLA-B8-restricted overlapping peptides inclusive of this lysine could bind to HLA-B8 and could be used to elicit T-cell proliferative responses when the peptide was either pulsed onto HLA-matched normal antigen presenting cells or onto HLA-B8 positive CML cells (Bocchia et al., 1995 (Bocchia et al., , 1996 Dermime et al., 1995) . However, when the b3a2 peptides were used to elicit b3a2-specific T-lymphocyte lines in vitro, the resulting Tcells could not specifically lyse fresh CML cells which had not previously been pulsed with the peptide (Bocchia et al., 1996) . This could be due to a low affinity of the peptide-specific CTL or the peptide may not be processed or presented on CML cells. More recently, however, b3a2-specific CTL were identified in the peripheral blood of CML patients using soluble b3a2 peptide/MHC tetramers (Clark et al., 2001) . Although the tetramer-positive CTL from the patients were not tested to determine whether they could kill CML targeT-cells, b3a2-specific CTL elicited in vitro from healthy donors were able to kill CML cells. This suggests that bcr -abl fusion peptides may be the targets of GVL reactions.
In tumors other than leukemia, such as melanoma and breast cancer, many peptide antigens have been identified that are the targets of tumor-specific CTL. What is clear from these studies is that nearly all of the tumor antigens identified as targets of tumor-specific CTL are derived from normal tissue proteins (Boon et al., 1997; Nanda and Sercarz, 1995) . It is now accepted that many self-antigenic determinants have not induced self-tolerance and that these peptide determinants supply target structures for autoimmune attack (Nanda and Sercarz, 1995; Rosenberg and White, 1996) . Since these proteins are often aberrantly expressed or overexpressed in the tumor there is relative tumor specificity by CTL that recognize these epitopes (Pardoll, 1994 (Pardoll, , 2002 .
Melanoma peptide antigens that are derived from MAGE-3 proteins, for example, are presented to melanoma-specific CTLs in the context of HLA-A1 and -A2 alleles (Gaugler et al., 1994; Tanaka et al., 1997; van der Bruggen et al., 1994) . This protein belongs to a family of proteins that are expressed in melanoma cells and in normal testis, and a MAGE-3 derived peptide was determined to be immunogenic by two separate groups of investigators using different techniques, one using an immunological method (Celis et al., 1994) and the other a genetic method (using Tcell clones to screen tumor antigen-deficient mutants) (Gaugler et al., 1994) . A phase I clinical trial using MAGE-3 peptides to vaccinate melanoma patients resulted in some clinical responses (Marchand et al., 1995) . In addition, tyrosinase, gp100, and Melan-A-MART-1, normal self-proteins that are expressed only in the melanocyte lineage, have determinants recog-nized by T-cells in a large majority of melanoma patients Zarour et al., 1996) . Two recent phase II vaccine trials demonstrated clinical efficacy of active immunotherapy using these target antigens either as a peptide vaccine or as an antigenpulsed dendritic cell vaccine. What may be critical for selective tumor-specific destruction by CTL specific for these targets is the density of the overexpressed peptide-MHC complexes, as well as the expression of costimulatory signals that influence activation of the otherwise silent tumor-specific T-cell repertoire (Nanda and Sercarz, 1995) .
To adapt what has been learned about immunity against these melanoma antigens to the study of myeloid leukemia antigens, we studied myeloid-restricted proteins that are highly expressed in the leukemia relative to normal hematopoietic progenitors. Myeloid leukemias express a number of differentiation antigens associated with granule formation. An example of an aberrantly expressed tumor antigen in human leukemia is proteinase 3 (Pr3), a 26 kDa neutral serine protease that is stored in primary azurophil granules and is maximally expressed at the promyelocyte stage of myeloid differentiation (Chen et al., 1994; Muller-Berat et al., 1994; Sturrock et al., 1992) . Pr3 and two other azurophil granule proteins, neutrophil elastase and azurocidin, are coordinately regulated and the transcription factors PU.1 and C/EBPa, which are responsible for normal myeloid differentiation from stem cells to monocytes or granulocytes, are important in mediating their expression (Zhang et al., 2002) . In particular, PU.1 induces expression of the macrophage colony-stimulating factor receptor and the development of monocytes, whereas C/EBPa increases the expression of the granulocyte colony-stimulating factor receptor and leads to mature granulocytes (Behre et al., 1999; Zhang et al., 2002) . These transcription factors have been implicated in leukemogenesis (Behre et al., 1999) , and Pr3 itself may also be important in maintaining a leukemia phenotype since Pr3 antisense oligonucleotides halt cell division and induce maturation of the HL-60 promyelocytic leukemia cell line (Bories et al., 1989) .
We have also studied another myeloid-restricted protein, myeloperoxidase (MPO), a heme protein synthesized during very early myeloid differentiation that constitutes the major component of neutrophil azurophilic granules. Produced as a single chain precursor, myeloperoxidase is subsequently cleaved into a light and heavy chain. The mature myeloperoxidase enzyme is composed of two light chains and two heavy chains (Borregaard and Cowland, 1997 ) that produces hypohalous acids central to the microbicidal activity of netrophils. Importantly, MPO and Pr3 are both overexpressed in a variety of myeloid leukemia cells including 75% of CML patients, approximately 50% of acute myeloid leukemia patients, and approximately 30% of myelodysplastic syndrome patients (Dengler et al., 1995) .
What may be critical for our ability to identify T-cell antigens in these proteins is the observation that Pr3 is the target of autoimmune attack in Wegener's granulomatosis (Franssen et al., 1996) and MPO is the target antigen in small vessel vasculitis (Borregaard and Cowland, 1997; Brouwer et al., 1994; Franssen et al., 2000) . There is evidence for both T-cell and humoral immunity in patients with these diseases. Wegener's granulomatosis is associated with production of cytoplasmic anti-neutrophil cytoplasmic antibodies (cANCA) with specificity for Pr3 (Williams et al., 1994) , while microscopic polyangiitis and Churg -Strauss syndrome are associated with the production of perinuclear ANCA (pANCA) antibodies with specificity for MPO (Jennette et al., 2001; Savige et al., 1999) . T-cells taken from affected individuals proliferate in response to crude extracts from neutrophil granules and to the purified proteins (Ballieux et al., 1995; Brouwer et al., 1994) . These findings suggest that T-cell responses against these proteins might be relatively easy to elicit in vitro using a deductive strategy to identify HLA-restricted peptide epitopes. Based on this hypothesis, we identified PR1, an HLA-A2.1-restricted nonamer derived from Pr3, as a leukemia-associated antigen (Molldrem et al., 1996 (Molldrem et al., , 1997 (Molldrem et al., , 1999 by first searching the length of the protein using the HLA-A2.1 binding motif, the most common HLA allele. Peptides predicted to have high affinity binding to HLA-A2.1 were synthesized, confirmed to bind, and then used to elicit peptidespecific cytotoxic T-lymphocytes (CTL) in vitro from healthy donor lymphocytes.
We have found that PR1 can be used to elicit CTL from HLA-A2.1+ normal donors in vitro, and that Tcell immunity to PR1 is present in healthy donors and in many patients with CML that are in remission. These PR1-specific CTL show preferential cytotoxicity toward allogeneic HLA-A2.1+ myeloid leukemia cells over HLA-identical normal donor marrow (Molldrem et al., 1996) . In addition, PR1-specific CTL inhibit colony-forming unit granulocyte -macrophage (CFU -GM) from the marrow of CML patients, but not CFU -GM from normal HLA-matched donors (Molldrem et al., 1997) , suggesting that leukemia progenitors are also targeted.
Using PR1/HLA-A2 tetramers to detect CTL specific for PR1 (PR1 -CTL), we found a significant correlation with cytogenetic remission after treatment with interferon-a and the presence of PR1 -CTL . Somewhat surprisingly, PR1 -CTL were also identified in the peripheral blood of some allogeneic transplant recipients who achieved molecular remission and who had converted to 100% donor chimerism. PR1/HLA-A2 tetramer-sorted allogeneic CTL from patients in remission were able to kill CML cells but not normal bone marrow cells in 4 h cytotoxicity assays, thus demonstrating that the PR1 self-antigen is also recognized by allogeneic CTL . These studies have established PR1 as a human leukemia-associated antigen and they established that PR1-specific CTL contribute to the elimination of CML .
Recently, we found another peptide, MY4, a nine amino acid peptide derived from MPO that binds to HLA-A2.1, which can be used to elicit CTL from HLA-A2.1+ normal donors in vitro (Braunschweig et al., 2000) . MY4-specific CTL show preferential cytotoxicity toward allogeneic HLA-A2.1+ myeloid leukemia cells over HLA-identical normal donor marrow (Braunschweig et al., 2000) . MY4-specific CTL also inhibit CFU -GM from the marrow of CML patients, but not CFU -GM from normal HLAmatched donors. Like PR1, MY4 is therefore a peptide antigen that can elicit leukemia-specific CTL.
Because of the many striking similarities between immunity to Pr3 and MPO, it is likely that similar methods applied to the study of immunity against MPO-derived peptides will establish MY4 and other peptides as important leukemia-associated antigens (Kochenderfer and Molldrem, 2001) . Using a deductive strategy to uncover potential tumor antigens, we are currently studying sequence data from the human genome project to determine other HLA-restricted epitopes from tissue-restricted antigens. There is a high likelihood that other peptide epitopes can be determined using this approach, especially by focusing on those proteins that are already the known targets of Tcell-mediated autoimmunity.
More recently, we have shown that distinct populations of PR1 -CTL with either high or low TCR affinity for PR1 can be elicited from PBMC of healthy donors. The high affinity PR1 -CTL cause higher specific lysis of CML cells than low-affinity PR1 -CTL. Interestingly, we also found that when high affinity PR1 -CTL were exposed to target-cells that expressed high concentration of target antigen, the PR1 -CTL underwent apoptosis within 18 h. However, there was no apoptosis when the high-affinity PR1 -CTL were exposed to a 2-log lower concentration of PR1 antigen. Furthermore, we have been unable to either detect or elicit high-affinity PR1 -CTL in vitro from PBMC of untreated CML patients. Since healthy HLA-A2+ individuals have PR1 -CTL with highaffinity TCR, however, this suggests that the highaffinity PR1 -CTL may have been deleted during the outgrowth of the leukemia by CML cells that overexpress the PR1 tumor antigen.
Taken together, these findings suggest that, in addition to HLA disparities and polymorphic mHAs, self-antigens may be the targets of alloreactive T-cells. These observations form the basis for a mechanism of alloreactivity and subsequent new treatment strategies based on targeting self-antigens in the allogeneic setting. Specifically, GVL alloreactivity may in part be due to the transfer from donor to recipient of high affinity CTL with leukemia self-antigen specificity that were not deleted from the T-cell repertoire during normal T-cell development in the donor. On this basis, GVL could be separated from GVHD if the target selfantigen expression was limited to hematopoietic tissue only. Further specificity from aberrant expression of the target self-antigen in the leukemia compared to normal hematopoietic cells might give rise to a critical number of recognizable surface peptide epitopes that would surpass the activation threshold of high affinity T-cells, whereas the lower level of antigen expressed in the normal hematopoietic cells would not. This would result in preferential killing and elimination of leukemia cells over normal hematopoietic cells by the transplanted high affinity donor T-cells. As a consequence, residual normal recipient hematopoietic cells would be spared and could then co-exist with donor hematopoietic cells after successful elimination of the leukemia, a phenomenon that occurs in some BMT recipients that achieve cytogenetic remission.
Arguing against this hypothesis is the observation that CML recipients of syngeneic stem cell grafts, which have few mHA differences but which should also contain high-affinity PR1 -CTL, suffer higher relapse rates than do recipients of allogeneic grafts (Gale et al., 1994) . However, because high-affinity PR1 -CTL are present at a very low precursor frequency in healthy donors, major and minor histocompatibility antigenic differences may be required to provide generalized heighten immunity, via indirect effects mediated by cytokine secretion, which might broadly decrease the threshold of TCR activation and drive the expansion of high-affinity self-antigen-specific T-cells. This would also explain the development of GVHD, since this could lead to the uncovering of cryptic antigens and also to epitope spreading (Anderton and Wraith, 2002) . More effective GVL might therefore be observed after syngeneic BMT if higher numbers of high-affinity CTL were initially transplanted. Consistent with this is the clinical observation that fewer relapses occur in syngeneic graft recipients who receive higher total nucleated cell doses during initial transplant (Barrett et al., 2000) , suggesting that an initially high number of high-affinity self-antigen specific CTL might compensate for their innately low precursor frequency and the absence of significant alloreactivity in this setting.
In summary, we are beginning to learn more about the nature of the antigens targeted by T-cells that mediate the GVL effect. If more antigens were identified, logical immunotherapy strategies such as vaccines or adoptive cellular therapies could be tested in patients. Obstacles to this approach remain, however. We must identify which of the hematopoietic tissue-restricted peptides are recognized by T-cells and we must improve our understanding of the nature of peripheral T-cell tolerance so that we might break immune tolerance to certain peptide determinants without causing autoimmunity. In the future, allogeneic stem cell transplantation is likely to evolve as a platform for delivering antigen-specific adoptive cellular therapy involving the transfer of donor-derived Tcells with the appropriate antigen specificity.
